🧬 777 (@Biotech777) profile picture

the simpler. the better. I mostly tweet about $AFMD

Joined October 2018
Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)Photo by 🧬 777 (@Biotech777)
🧬 777 retweeted
Replying to @graham74GC
Thanks to german managers incompetence at @affimed, this (and other) asset is on sale through the german insolvency rules. $AFMD $AFMDQ
2
3
10
980
🧬 777 retweeted
Confirmed delay for those 5 pts which will be reported on Q3 $AFMD
Another user @Biotech777 already posted it. They explained it very well.
2
1
10
1,678
Bi-specific Antibodies in Oncology 11 approvals since 2009 $JNJ Tecvayli (BCMAxCD3) $JNJ Rybrevant (EGFRxMET) $RHHBY Talvey (GPRC5DxCD3) $ABBV CD20xCD3 $AMGN tarlatamab (DLL3xCD3) Source: Jeffries
4
12
1
38
10,592
🚨Reminder AACR Regular Abstract Titles and Texts Posted to Online Itinerary Planner (4:30 p.m. ET) See companies who have already announced presentations on the Conference Calendar: biopharmcatalyst.com/calenda… Get company press releases straight to your browser or email here: biopharmcatalyst.com/account…
2
1,730
#ASH23 Abstract 774 - Yago Nieto et al. @lab_rezvani CB-derived CIML ex vivo expanded NK cells precomplexed with the bispecific AFM13 construct shows high response rates in pts with CD30+ lymphoma, double refractory to brentuximab vedotin and checkpoint inhibitors. Promising!
1
4
1
18
3,064
For patients with refractory CD30+ lymphomas, a promising new therapy: cord blood-derived NK cells that were preactivated and expanded then complexed with the innate cell engager AFM13. Data presented at #ASH23 by our Dr. Yago Nieto. Read more: bit.ly/46KHxgi #EndCancer – at San Diego, CA
8
4
17
7,509
1
3
11
1,248
Replying to @BrianUherek
Just finished voting; voted against the whole board and against reverse split too. Urge every investor in $AFMD to vote, and consider that current management treats the company as their own personal science experiment, and the shareholders as their unlimited piggybank.
1
3
14
817
.@affimed In order they asked to reappoint the current management (8) and to authorize a R/S (10). They are SHAMELESS. Especially in light of their 2022 compensation (stock dropped 90%). Every investors - especially they big fund - should vote AGAINST those two points. $AFMD
Replying to @affimed
@Affimed $AFMD So deserved! Fantastic! 👏👏
4
13
1,969
Long overdue. At least it's a sign that mgmt...finally, finally...understands that they have mismanaged and miscalculated. $AFMD
Replying to @RNA_Biotech
$AFMD reduces headcount by 25% "In April 2023, Affimed conducted a reorganization of its operations to focus on its three clinical programs. As a result, the Company reduced its full-time equivalent headcount by approximately 25 percent."
1
4
1
16
5,490
Hello BioTwitter. Please support with likes my LinkedIn post, where i'm asking tough questions to $AFMD team and its CEO - Adi Hoess specifically, As investors we need to be active to save our money! linkedin.com/in/nikolai-briu…
1
1
1
6
2,337
Replying to @Biotech777
$FATE cell engineering very advanced and fancy, & complicated too, reminding what a professor of mine said on a fancy experimental design: “It didn’t work!”. My hunch? $FATE will be cut down by Occam's razor. $AFMD tech is simple, the simple as in KISS! $ARKG analysts r 2 young
2
2
8
🧬 777 retweeted
$FATE iPSC + anti-pdl1 mAb data to be released at SITC. If no responses, further validation of $AFMD approach with ICEs becoming “The keytruda of NKCEs”.
Replying to @RNAiAnalyst
BIGGER repeat * let others build (CAR-)NK cell capabilities of all kind & partner their cells with own or partnered targets * let others execute trials & take risks * cash in upfront, milestones & royalties until $AFMD is the Keytruda 4 NK-cell industry everybody needs & wants
2
7
23
🧬 777 retweeted
$AFMD innate cell engagers at #SITC22 should be interesting for @affimed’s own/partnered molecules and for combinations development (but again we need stronger management). Ps. Artiva’s AB101 data will be relevant for Affimed (t/t @dhovekamp42) not sure it will FATE data
2
8
🧬 777 retweeted
AFVT-2101 (aka AFM32), an innate immune-cell engager that selectively targets FOLR1 expressing tumor cells to safely harness potent anti-cancer responses. At #SITC2022 cc $AFMD $ROIV
1
4
1
17
Replying to @genentech
Very interesting. Look at the more effective and safer NK cell engagers + NK cells developed by your partner #Affimed. The MoA of the NKCEs at the microscopy looks quite interesting (and powerful). Curious to see your new partnered NKCE(s)! Paper: science.org/content/article/…
2
6
NK Cells Complexed with CD30/CD16A Bispecific Antibody Offers Potential Treatment for R/R Lymphoma oncologydirectory.com/news/n…
2
2
There is nothing more amazing in one’s career than having a preclinical concept translated to the clinic. Congratulations @lucila_kerbauy, everyone in the lab, the MDACC cord bank and GMP, and especially Dr Nieto and the clinical team. @ScienceMagazine @MDAndersonNews #AACR2022 – at Houston, TX
6
21
2
173
Cantor Fitzgerald reiterates $AFMD Overweight/$12PT~stock remains one of firm's top ideas for '22, believes the updated data of AFM13 + NK combo lend strong support to their best-case scenario
2
17
🧬 777 retweeted
Lymphoma patients are not always responsive to current therapy options. Affimed’s mission to revolutionize the treatment landscape starts with AFM13, a novel approach of activating the #InnateImmunity against cancer: https://nitter.cf/t.co/gqdRxBVFKT #InnatelyAffimed #AFM13
6
2
23